Pharnext Stock Quote ALPHA - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.0002

Bid

0.0001

Ask

0.0002

Volume

0.00

0.00 Day's Range 0.00

0.0001 52 Week Range 1.21

Market Cap

17.505

Previous Close

0.0002

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

0.00

Shares Outstanding

87,525

Dividend Yield

PE Ratio

-79,519.02

Earnings Per Share (EPS)

-314.39

Revenue

174k

Net Profit

-27.52M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

pharnext.com/

Headquarters

Suresnes, Hauts-de-seine, Fra

Founded

Pharnext is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALPHA. The last closing price for Pharnext was 0.00 €. Over the last year, Pharnext shares have traded in a share price range of 0.0001 € to 1.21 €.

Pharnext currently has 87,525 shares outstanding. The market capitalization of Pharnext is 17.51 € . Pharnext has a price to earnings ratio (PE ratio) of -79519.02.

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday...

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time

New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New Data from the...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with ...

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traiteme...

Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de...

Europäische Arzneimittelagentur stimmt dem pädiatrischen Prüfkonzept für PXT3003 von Pharnext zu

Diese Zustimmung bereitet den Weg für die Stellung eines Marktzulassungsantrags in Europa Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), ein biopharmazeutisches Unternehmen und...

European Medicines Agency Agrees with Pharnext’s Pediatric Investigation Plan for PXT3003

This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a...

Pharnext will Topline-Ergebnisse der zulassungsrelevanten Phase-3-Studie zu PXT3003 zur Behandlung der Charcot-Marie-Tooth-Kr...

Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter eines neuen Ansatzes zur Entwicklung innovativer Medikamentenkombinationen, die auf Big...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0.0002	0.0002	0.0002	0	0	DE
4	0	0	0.0002	0.0002	0.0002	0	0	DE
12	0	0	0.0002	0.0002	0.0002	0	0	DE
26	-0.0001	-33.3333333333	0.0003	0.0003	0.0001	1627064	0.00017297	DE
52	0.0001	100	0.0001	1.21	0.0001	8316163	0.00072964	DE
156	-0.0894	-99.7767857143	0.0896	1.95	0.0001	60817071	0.00231093	DE
260	-6.3598	-99.9968553459	6.36	6.68	0.0001	37643458	0.0071145	DE

ALPHA - Frequently Asked Questions (FAQ)

What is the current Pharnext share price?

The current share price of Pharnext is 0.0002 €

How many Pharnext shares are in issue?

Pharnext has 87,525 shares in issue

What is the market cap of Pharnext?

The market capitalisation of Pharnext is EUR 17.51

What is the 1 year trading range for Pharnext share price?

Pharnext has traded in the range of 0.0001 € to 1.21 € during the past year

What is the PE ratio of Pharnext?

The price to earnings ratio of Pharnext is -79.52k

What is the cash to sales ratio of Pharnext?

The cash to sales ratio of Pharnext is 12.58M

What is the reporting currency for Pharnext?

Pharnext reports financial results in EUR

What is the latest annual turnover for Pharnext?

The latest annual turnover of Pharnext is EUR 174k

What is the latest annual profit for Pharnext?

The latest annual profit of Pharnext is EUR -27.52M

What is the registered address of Pharnext?

The registered address for Pharnext is 14 RUE DE LA REPUBLIQUE, SURESNES, HAUTS-DE-SEINE, 92150

What is the Pharnext website address?

The website address for Pharnext is pharnext.com/

Which industry sector does Pharnext operate in?

Pharnext operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ALCYBCybergun	0.0002 € (100.00%)	63.2M
TUVDSBio UV Group DS	0.015 € (70.45%)	490.92k
CANDCandela Invest	1.70 € (70.00%)	42
BIODSBiosynex DS	0.07 € (39.44%)	55.52k
ALGTRGroupe Tera SA	4.10 € (25.77%)	17.71k
MLIMLImalliance	0.282 € (-27.32%)	1.5k
ALCARCarmat	0.822 € (-22.60%)	3.04M
MLOCTOctopus Biosafety	0.14 € (-21.35%)	18.55k
ALEXPOne Experience	0.386 € (-21.22%)	933
SNGSonagi	0.80 € (-20.00%)	800
ATOAtos SE	0.0023 € (4.55%)	608.11M
ALVERVergnet	0.0011 € (0.00%)	92.88M
ALCYBCybergun	0.0002 € (100.00%)	63.2M
BCPBanco Comercial Portugues SA	0.5054 € (0.04%)	32.95M
ALHPIHopium SA	0.0028 € (-6.67%)	15.99M